Nutex Health: The Stock Has Had A Great Run, But New Guidance Justifies A Higher Target Price (Rating Upgrade)

Summary Nutex Health is rated Strong Buy, with a new target price of $290.43, representing 39.1% upside from current levels. NUTX's profitability and growth metrics significantly outpace peers, driven by effective use of the No Surprises Act and disciplined cost controls. Consensus EPS projections for FY2026 and FY2027 have materially increased, with FY2026 EPS now expected at $27.79, supporting a forward PE of just 10.5. Despite elevated short interest (16.98%), robust fundamentals and potential for a short squeeze reinforce the bullish thesis. nzphotonz/iStock via Getty Images Investing Thesis When I last valued Nutex Health Inc. ( NUTX ), I arrived at a target price of $199.31 . Since then, the stock advanced to its current price of $208.82, 4.8% higher than my old target price. Given the release This article was written by Adam Schadt 72 Followers Follow I have an MBA from the University of Rochester's Simon Business School and six years experience doing private business valuations. I've always had a fascination with investing (I bought my first stock in my late teens) and enjoy actively managing my personal portfolio. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.